Psychological and psychiatric perspective on the treatment of chronic pain

Chronic pain is a complex global health problem that requires a multimodal and multidisciplinary approach for effective treatment. The integration of psychotherapeutic, pharmacological, and physical therapy in the joint work of medical teams improves patient outcomes. A proactive psychological and psychiatric approach identifies key psychological and social factors contributing to the onset of chronic pain and allows for the selection of the necessary therapeutic methods: pharmacological (duloxetine, pregabalin, cannabinoids), non-pharmacological (personalized cognitive behavioral therapy, individual cognitive behavioral therapy-techniques), technological (VR-technologies, TMS) to develop individualized interventions. In turn, personalized strategies improve physical function, mental health, and quality of life, while reducing pain chronicity.

References

1. Staudt M.D. The Multidisciplinary Team in Pain Management. Neurosurg Clin N Am. 2022 33(3): 241–249. doi: 10.1016/j.nec.2022.02.002.
2. Асанова А, Мухаровська I Дослідження психічних феноменів в структурі хронічного болю: депресія, тривога, катастрофізація. Огляд літератури. PMGP, 8(4): e0804505.
3. Khaustova OO, Markova MV, Driuchenko MO et al. Proactive psychological and psychiatric support of patients with chronic non-communicable diseases in a randomised trial: a Ukrainian experience. Gen. psychiatry. 2022; 35(5). e100881.
4. Khaustova O, Assonov D, Asanova А (2021) Proactive psychosomatic approach to the post-COVID depression treatment. Psychosomatic Medicine and General Practice. 2021; 6(3). doi.org/10.26766/pmgp.v6i3.339.
5. Asanova А, Ovdii М, Mukharovska І, Skrynnyk О The role of catastrophizing, depression and anxiety in chronic pain: a cross-sectional pilot study. International neurological journal. 2024; 20(7). 334–342.
6. Nice guidline [NG193] Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. 07 April 2021.
7. Asanova А, Khaustova О Typical difficult situations in doctor-patient interactions. PMGP. 2018;3(3): e0303125. doi.org/10.26766/pmgp.v3i3.125.
8. McNaughton MA Shared Journey: Effective communication tools to successfully navigate the patient-provider relationship. Pain Management Nursing 2024; 25(2): e159. doi: 10.1016/j.pmn.2024.02.038.
9. Chapman CR, Woo NT, Maluf KS Preferred Communication Strategies Used by Physical Therapists in Chronic Pain Rehabilitation: A Qualitative Systematic Review and Meta-Synthesis. Phys Ther Rehab J 2022; 102(9):1-16. doi: 10.1093/ptj/pzac081
10. Haverfield МС, Giannitrapani KF, Timko C et al. Patient-Centered Pain Management Communication from the Patient Perspective. J Gen Int Med 2018; 33(8): 1374-1380.
11. Мухаровська І, Асанова А Психологічні складові проблеми професійної комунікації у ситуації повідомлення діагнозу та несприятливих новин. Психосоматична медицина та загальна практика. 2024 9(1).
12. Correia J, Waqas A, Assal J-P et al. Effectiveness of therapeutic patient education interventions for chronic diseases: A systematic review and meta-analyses of randomized controlled trials. Front Med. 2023. doi: 10.3389/fmed.2022.996528
13. Чабана ОС, Хаустова ОО Комунікативні навички лікаря: підручник для студентів вищих медичних навчальних закладів. За заг. редакцієй О.С. Чабана, О.О. Хаустової, І.А. Коваль. Національний медичний університет ім. О.О.Богомольця. Київ: Медпринт. 2022, 400 с.
14. Lee J, Lazaridou A, Paschali M et al. A Randomized Controlled Neuroimaging Trial of Cognitive Behavioral Therapy for Fibromyalgia Pain. Arthritis Rheumatol. 2024 76(1): 130-140. doi: 10.1002/art.42672.
15. Bishop J, Shpaner M, Kubicki A et al. Structural Neuroplasticity Following Cognitive Behavioral Therapy for the Treatment of Chronic Musculoskeletal Pain: A Randomized Controlled Trial with Secondary MRI Outcomes. medRxiv. 2021.
16. Ploutarchou G, Savva C, Karagiannis C et al. The effectiveness of cognitive behavioural therapy in chronic neck pain: A systematic review with meta-analysis. Cogn Behav Ther. 202 52(5): 523-563. doi: 10.1080/16506073.2023.2236296.
17. Zhang Q, Xu H, Wang Y et al. Efficacy of cognitive behavioral therapy for reducing pain susceptibility and increasing social engagement in patients with chronic low back pain: A systematic review and meta-analysis. Medicine (Baltimore). 2023 Nov 10;102(45):e35269. doi: 10.1097/MD.0000000000035269.
18. Sanabria-Mazo JP, Colomer-Carbonell A, Fernández-Vázquez Ó et al. A systematic review of cognitive behavioral therapy-based interventions for comorbid chronic pain and clinically relevant psychological distress. Front Psychol. 2023 Dec 22;14:1200685. doi: 10.3389/fpsyg.2023.1200685.
19. McCracken LM, Yu L, Vowles KE New generation psychological treatments in chronic pain. BMJ. 2022 Feb 28;376:e057212. doi: 10.1136/bmj-2021-057212.
20. Moulin DE, Boulanger A, Clark A et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society // Pain Res Manag. 2014;19(6): 328–335.
21. Attala N, Cruccua G et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113–1123.
22. Finnerup NB, Attal N et al. Pharmacotherapy for neuropathic pain in adults: systematic review, meta-analysis and updated NeuPSIG recommendations. Lancet Neurol. 2015 4(2): 162–173.
23. Bair MJ et al. Depression and pain comorbidity: a literature review. Archives of Internal Medicine. 2003; 163(20): 2433–2445.
24. Bing Hu Duloxetine usage in depression. 2021; 357–368.
25. Nodera H Medical Treatment of Chronic Pain. Brain Nerve. 2023 75(3): 227–234.
26. Marcus DA Duloxetine use in painful conditions. Expert Opinion on Pharmacotherapy. 2011;12(8):1333-1340. doi: 10.1517/14656566.2011.580739
27. Skljarevski V, Zhang S, Iyengar S et al. Efficacy of Duloxetine in Patients with Chronic Pain Conditions. Current Drug Therapy. 2011 6(4): 296–303.
28. Birkinshaw Н, Friedrich С, Cole Р et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Health Technology Assessment. 2024; 28(62): 1–155. doi: 10.3310/mkrt2948
29. Valenzuela-Fuenzalida JJ, López-Chaparro M, Barahona-Vásquez, Javiera M et al. Effectiveness of Duloxetine versus Other Therapeutic Modalities in Patients with Diabetic Neuropathic Pain: A Systematic Review and Meta-Analysis. Pharmaceuticals. 2024; 17(7): 856-856. doi: 10.3390/ph17070856
30. Mease PJ, Walker DJ, Alaka K Evaluation of duloxetine for chronic pain conditions. Pain management. 2011;1(2):159-170. doi: 10.2217/PMT.11.4
31. Sun J, Wang L, Guo Y Efficacy and safety of duloxetine in chronic musculoskeletal pain: a systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2023; 24(1) doi: 10.1186/s12891-023-06488-6
32. Alles SRA, Cain SM, Snutch TP Pregabalin as a Pain Therapeutic: Beyond Calcium Channels. Frontiers in Cellular Neuroscience. 2020; 14: 83–83.
33. Gajraj NM Pregabalin: its pharmacology and use in pain management. Anesthesia & Analgesia. 2007; 105(6):1805-1815. doi: 10.1213/01.ANE.0000287643.13410.5E
34. Rakusa M, Marolt I, Stevic Z et al. Efficacy of Pregabalin and Duloxetine in Patients with Painful Diabetic Peripheral Neuropathy (PDPN): A Multi-Centre Phase IV Clinical Trial—BLOSSOM. Pharmaceuticals. 2023; 16(7): 1017.
35. Taguchi T et al. Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study. Japan J Pain Res 2015: 8487–497.
36. Crofford LJ, Rowbotham MC, Mease PJ et al. Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 52(4): 1264–1273.
37. Baldwin DS, den Boer JA, Lyndon G et al. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. J Psychopharmacol. 2015 29(10): 1047–1060. doi: 10.1177/0269881115598411.
38. Shetty A, Delanerolle G, Cavalini H et al. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain. Dental science reports. 2024; 14(1). doi: 10.1038/s41598-023-49761-3
39. Nikolaienko V. Pain, anxiety, sleep disturbances — three targets for pregabalin with neuropathic back pain. Int Neurol J. 2018; 52–55.
40. Guay D Pregabalin in neuropathic pain: a more «pharmaceutically elegant» gabapentin? Am J Geriatr Pharmacother 2005; 3(4): 274–287.
41. Cásedas G, Yarza-Sancho M, López V. Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain. Pharmaceuticals (Basel). 2024 17(11): 1438. doi: 10.3390/ph17111438.
42. Nascimento GC, Escobar-Espinal D, Bálico GG et al. Cannabidiol and pain. Int Rev Neurobiol. 2024;177: 29–63. doi: 10.1016/bs.irn.2024.04.016.
43. Mohammed SYM, Leis K, Mercado RE et al. Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review. Pain managment nursing. 2024; 25(2); e76–e86. https://doi.org/10.1016/j.pmn.2023.10.002
44. Reechaye D, Perrine ALA, Jahajeeah Y et al. Cannabinoids as a Natural Alternative for the Management of Neuropathic Pain: A Systematic Review of Randomized Placebo-Controlled Trials. Cureus. 2024 16(9): e70021. doi: 10.7759/cureus.70021.
45. Naya NM, Kelly J, Corna G et al. Molecular and Cellular Mechanisms of Action of Cannabidiol. Molecules. 2023 28(16): 5980. doi: 10.3390/molecules28165980.
46. Kowalczyk K Medical cannabis: Mechanisms of action and therapeutic targets. J Educational Health and Sports. 2024; 58: 176–190 doi:10.12775/JEHS.2024.58.013
47. Borges JUV Mitigating the Opioid Epidemic: The Role of Cannabinoids in Chronic Pain Management — A Systematic Review and Meta-Analysis of Clinical Evidence and Mechanisms. Research square. 2024. doi: 10.21203/rs.3.rs-4736592/v1
48. Hladkykh F Multimodal Analgesia: Polypharmacy in Pain Relief or Rational Use of Non-Steroidal Anti-Inflammatory Drugs to Prevent Pain Chronicity. Path of Science. 2020; 6(7): 4008–4018. doi: 10.22178/POS.60-5
49. Slater D, Kunnathil S, McBride J, Koppala R. Pharmacology of nonsteroidal antiinflammatory drugs and opioids. Semin Intervent Radiol. 2010 27(4): 400–411.
50. Saad J, Mathew D. Nonsteroidal Anti-Inflammatory Drugs Toxicity. 2021.
51. Senthilnathan V, Priyadharshini V et al. From Pain Relief to Cancer Defense: The Promise of NSAIDs. J Advanc Med Pharmaceut Sci. 2023.
52. Ho K-Y, Gwee KA, Cheng YK. Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice. J Pain Res 2018; 11: 1937–1948.
53. Bach-Rojecky L, Vađunec D, Žunić K et al. Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids. Personalized Medicine 2019; 16(2): 171–184. doi: 10.2217/PME-2018-0116
54. David G, Lambert. Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis. BJA open. 2023; 6: 100141–100141. doi: 10.1016/j.bjao.2023.100141
55. Dowell D, Ragan KR, Jones CM et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. Recommendations and Reports/ November 4, 2022; 71(3):1–95. https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm
56. Nadeau SE, Jeffrey, Wu JK et al. Opioids and Chronic Pain: An Analytic Review of the Clinical Evidence. Frontiers in pain research. 2021. doi: 10.3389/FPAIN.2021.721357
57. Sloan PA, Davis MP. Extended-release and long-acting opioids for chronic pain management. J Opioid Manag. 2015; Suppl: 3–10. doi: 10.5055/jom.2014.0228.
58. Russell C, Law J, Bonn M. The increase in benzodiazepine-laced drugs and related risks in Canada: The urgent need for effective and sustainable solutions. International J.of Drug Policy. 2023; 111.
59. Liebschutz J, Beers D, Lange A. Managing Chronic Pain in Patients with Opioid Dependence. Current treatment options in psychiatry. 2014; 1(2): 204–223.
60. Alemanno F, Houdayer E, Emedoli D et al. Efficacy of virtual reality to reduce chronic low back pain: Proof-of-concept of a non-pharmacological approach on pain, quality of life, neuropsychological and functional outcome. PLOS ONE. 2019; 14(5). doi: 10.1371/JOURNAL.PONE.0216858
61. Ceko M, Baeuerle T, Webster L. The effects of virtual reality neuroscience-based therapy on clinical and neuroimaging outcomes in patients with chronic back pain: a randomized clinical trial. Pain. 2024. doi: 10.1097/j.pain.0000000000003198
62. Giacomelli L, Martin Sölch C, Ledermann K. The effect of virtual reality interventions on reducing pain intensity in chronic pain patients: a systematic review. Virtual Reality. 2024; 28(3) doi: 10.1007/s10055-024-00994-1
63. Rizzo A, Bouchard S. Virtual Reality for Psychological and Neurocognitive Interventions. Virtual Reality Technologies for Health and Clinical Applications. Springer Nature 2019 https://doi.org/10.1007/978-1-4939-9482-3_1
64. Wang J. Virtual Reality Based Passive and Active Distraction Methods for the Treatment of Chronic Pain. 2021. doi: 10.26686/WGTN.14128943.V1
65. Joshi S, Mishra P, Shobit, Garg et al. Efficacy of transcranial magnetic stimulation in persistent somatoform pain disorder (psychosomatic pain): A narrative review. Archives of mental health. 2024. 25(2): 95–101. doi:10.4103/amh.amh_17_24
66. Jiang X, Yan W, Wan R. Effects of repetitive transcranial magnetic stimulation on neuropathic pain: A systematic review and meta-analysis. Neuroscince and Biobihavioral Review; 2021; 132(3). doi:10.1016/j.neubiorev.2021.11.037
67. Marchesi N, Govoni S, Allegri M. Non-drug pain relievers active on non-opioid pain mechanisms. Pain Practice, 2021. doi: 10.1111/PAPR.13073